Drug Profile
Pioglitazone deuterated - Poxel
Alternative Names: (R)-Pioglitazone deuterated - Poxel; Deuterated pioglitazone; Deuterium stabilised enantiomer pioglitazone; Deuterium-stabilized R-pioglitazone; DRX 065; PXL 065; R-Pioglitazone deuterated - PoxelLatest Information Update: 22 Nov 2023
Price :
$50
*
At a glance
- Originator DeuteRx
- Class Anti-inflammatories; Antihyperglycaemics; Hepatoprotectants; Indans; Neuroprotectants; Organic deuterium compounds; Phenyl ethers; Piperidines; Pyridines; Small molecules; Thiazolidinediones
- Mechanism of Action Mitochondrial membrane transport protein inhibitors; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- Phase I Adrenomyeloneuropathy
- Preclinical Adrenoleucodystrophy
Most Recent Events
- 08 Nov 2023 Poxel plans a phase IIa proof-of-concept biomarker trial in Adrenoleukodystrophy with initial focus on adrenomyeloneuropathy in 2023 (NCT05200104)
- 31 Jul 2023 Poxel has patent protection for Pioglitazone deuterated in the European Union
- 25 Jan 2023 Pioglitazone deuterated - Poxel receives Orphan Drug status for Adrenoleucodystrophy in European Union